Page 4 - Anjali Singh

Maruti Suzuki posts record sales, eyes faster path to next million vehicles

Maruti Suzuki expects small-car revival, new SUVs, capacity expansion and record exports to help it reach its next million-vehicle sales milestone sooner than anticipated

EV retail sales hit record high in July as adoption gathers pace

EV retail sales rose 66 per cent year-on-year to 327,901 units in July, pushing penetration to nearly 12 per cent as adoption accelerated across vehicle segments.

JK Tyre sees double-digit FY27 revenue growth despite input cost pressure

Robust domestic demand from original equipment manufacturers and the replacement market is expected to support growth, even as elevated input costs continue to weigh on margins

Biocon eyes stronger H2FY27 growth on back of recent US product launches

Biocon expects momentum to strengthen in H2FY27, driven by new US biosimilar and generic launches, improved operating leverage and a favourable product mix

International business to remain key driver for Emcure Pharma in FY27

Emcure expects overseas markets to drive growth in FY27 through product approvals, differentiated offerings and capacity expansion, while domestic business is seen improving

Eisai launches Alzheimer's drug Leqembi in India after CDSCO approval

The disease-modifying therapy for early Alzheimer's disease will cost ₹21,682 per vial, with treatment expenses varying according to patients' weight and dosage

OPPI seeks India-based start for regulatory data protection period

Industry body says it is open to a shorter regulatory data protection period if the clock starts from a drug's marketing approval in India rather than its first global approval

Sun Pharma Q1 profit rises 27%; US generics remain under pressure

Sun Pharma reported a 27 per cent rise in Q1FY27 profit, driven by India and innovative medicines, while weakness in the US generics business continued to weigh on growth

Piramal Pharma eyes mid-teens growth in FY27, prioritises organic expansion

Higher capacity utilisation, operating leverage and broad-based demand across CDMO, hospital generics and consumer healthcare are expected to support margins in FY27

As uncertainty becomes the new normal, M&M must enter attack mode: Mahindra

Mahindra Group chairman says prolonged global uncertainty offers prepared companies an edge, with India poised to emerge as a multi-aligned 'connector economy'

ChrysCapital acquires Novartis India, appoints Vikas Gupta as CEO

The private equity firm has taken control of the BSE-listed drugmaker, appointed Vikas Gupta as CEO and plans to build a branded generics platform in India

Sun Pharma to launch semaglutide in Brazil with Hypera Pharma soon

Sun Pharma will launch the once-weekly diabetes treatment through Hypera Pharma as generic competition intensifies in Brazil's $413 million semaglutide market

L&T bets ₹5,000 crore to become Tier-1 supplier in auto electronics market

Engineering major will invest over five years in EV motors, ADAS and connected-vehicle technologies, targeting a fast-growing market dominated by global players

JLR India posts record Q1 retail sales on strong luxury SUV demand

The company retailed 1,665 vehicles in Q1 FY27, up 11 per cent year-on-year, with the Range Rover, Range Rover Sport and Defender accounting for over 85 per cent of sales

Tata Motors' Gujarat plant hit by floods; Nexon, Sierra output disrupted

Flooding in Gujarat disrupts operations at Tata Motors' Sanand plant and supplier facilities, with production of key passenger vehicle models affected

Ramkrishna Forgings Q1 profit nearly quadruples; plans ₹170 crore capex

Forging company reports a 298 per cent jump in quarterly profit on higher revenue and margins, while approving ₹170 crore capex to expand passenger vehicle components business

Hero to TVS: Two-wheeler makers ride export wave, but watch road ahead

Hero, TVS, and Bajaj count on overseas markets while bracing for global uncertainty

Manipal IPO to be India's biggest in healthcare, seeks to raise ₹9,275 cr

₹9,275-crore issue opens on July 29 as the Temasek-backed hospital chain plans to add around 3,000 beds through greenfield and brownfield projects

Cipla's Q1 net falls 39% on US business; maintains FY27 margin guidance

The drugmaker attributed the decline to a high base in North America, retained its FY27 Ebitda margin guidance and expects new product launches to support growth

Mercedes-Benz India sees strong festive demand; new CLA sold out for 2026

The luxury carmaker expects 2026 to be its best-ever year, supported by robust order books, sustained demand across segments and strong festive-season momentum